Document is current
Any future updates will be listed below
-
Authors
Zhu, Ziwen https://orcid.org/0000-0002-6681-9153
Achreja, Abhinav https://orcid.org/0000-0002-1773-6490
Meurs, Noah
Animasahun, Olamide https://orcid.org/0000-0002-4032-3619
Owen, Sarah https://orcid.org/0000-0002-4102-7707
Mittal, Anjali
Parikh, Pooja
Lo, Ting-Wen https://orcid.org/0000-0002-2127-2000
Franco-Barraza, Janusz https://orcid.org/0000-0003-3652-5311
Shi, Jiaqi https://orcid.org/0000-0003-4893-1587
Gunchick, Valerie
Sherman, Mara H.
Cukierman, Edna https://orcid.org/0000-0002-1452-9576
Pickering, Andrew M.
Maitra, Anirban https://orcid.org/0000-0001-7923-9978
Sahai, Vaibhav https://orcid.org/0000-0003-1892-1548
Morgan, Meredith A. https://orcid.org/0000-0001-7965-6878
Nagrath, Sunitha https://orcid.org/0000-0002-1497-7977
Lawrence, Theodore S.
Nagrath, Deepak https://orcid.org/0000-0002-8999-2282
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (K08 CA234222, R01CA208335, R01CA227622, R01CA222251, R01CA204969)
- License Information
-
More Information
Article History
Received: 21 August 2019
Accepted: 28 May 2020
First Online: 6 July 2020
Competing interests
: A. Maitra receives royalties from Cosmos Wisdom Biotechnologies for a license related to a biomarker test for pancreatic cancer early detection. V.S. is a consultant at Halozyme, QED, Ipsen and Incyte. V.S. receives funding from Celgene, Bristol-Myers Squibb, Agios, Incyte, Clovis Oncology, Debiopharm Group, FibroGen, Halozyme, MedImmune, Rafael Pharmaceuticals and Ipsen. M.A.M. receives honoraria from AstraZeneca. S.N. is the named inventor on a patent for Microfluidic Labyrinth Technology granted to the University of Michigan. S.N. is a cofounders of Labyrinth Biotech. The funders and the company had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.
